NCT04300127View on ClinicalTrials.gov

Pioglitazone for Idiopathic Gastroparesis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 24, 2019

Primary Completion Date

March 15, 2025

Study Completion Date

March 18, 2025

Conditions
Gastroparesis
Interventions
DRUG

Pioglitazone 30 mg

Patients will received 30 mg of Pioglitazone once a day for 8 weeks

Trial Locations (1)

21224

Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT04300127 - Pioglitazone for Idiopathic Gastroparesis | Biotech Hunter | Biotech Hunter